LATEST RESEARCH NEWS BY ONCOTARGET:
- Experimental Triple Therapy Improves Survival in Glioblastoma Mouse Model
Researchers at Brown University have developed a combination treatment that significantly increases survival in mice with glioblastoma (GBM), a highly aggressive and treatment-resistant brain cancer. The approach uses a new class of drugs called imipridones along with radiation therapy and standard chemotherapy. - Engineered Proteins Show Promise in Stopping Glioblastoma Invasion
Scientists have engineered small, targeted proteins that can penetrate brain cancer cells and prevent them from invading healthy tissue, offering a promising new approach to treating glioblastoma multiforme (GBM), one of the deadliest forms of brain cancer. This strategy was developed by researchers at the University of Nevada, Reno, and published recently in Oncotarget. - Panitumumab and Low-Dose Capecitabine: A Promising Maintenance Therapy for Metastatic Colorectal Cancer
A recent study from Assiut University Hospital in Egypt, published in Oncotarget, presents a promising strategy for patients with metastatic colorectal cancer (mCRC). The research introduces a gentler yet effective maintenance therapy that may extend survival, enhance quality of life, and offer a more accessible treatment option for mCRC patients worldwide.
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | @Blagosklonny
ABOUT ONCOTARGET.ORG:
Oncotarget.org publishes weekly articles describing new and trending research papers published by Oncotarget—an open access biomedical journal dedicated to the publishing of the latest oncology-focused, peer-reviewed research papers. Visit Oncotarget.net to hear directly from the distinguished network of authors who continue to publish their research with Oncotarget. Readers may also find information about community news and events sponsored by Oncotarget at Oncotarget.net.
CONTACT INFORMATION:
For those interested in learning more about Oncotarget or in contacting the Journal, please visit the website.
For media inquiries, please contact media@impactjournals.com.